

Listing of Claims

Claims 1-8 (cancelled)

Claim 9. (previously amended) A method of suppressing excessive levels of GH in a patient in need of same which comprises administering to said patient an effective amount of a peptide selected from the group having the formulae:

X-R<sup>1</sup>-R<sup>2</sup>-Asp-Ala-R<sup>5</sup>-R<sup>6</sup>-Thr-R<sup>8</sup>-R<sup>9</sup>-R<sup>10</sup>-Arg-R<sup>12</sup>-R<sup>13</sup>-R<sup>14</sup>-R<sup>15</sup>-R<sup>16</sup>-Leu-R<sup>18</sup>-R<sup>19</sup>-Arg-R<sup>21</sup>-R<sup>22</sup>-Leu-Gln-Asp-Ile-R<sup>27</sup>-R<sup>28</sup>-R<sup>29</sup>-NH<sub>2</sub>

wherein X is PhAc, IndAc, or Nac,

R<sup>1</sup> is Tyr or His,

R<sup>2</sup> is D-Arg [or D-Cit],

R<sup>5</sup> is Ile or Val,

R<sup>6</sup> is Phe, Nal or Phe(Y), in which Y= Cl,

R<sup>8</sup> is Asn, Gln, Ala, or D-Asn,

R<sup>9</sup> is Arg, Har, Lys, Orn, D-Arg, D-Har, D-Lys, D-Orn, Cit, Nle, Tyr (Me), Ser, Ala or

Aib,

R<sup>10</sup> is Tyr or or Tyr(Me),

R<sup>12</sup> is Lys,

R<sup>13</sup> is Val or Nle,

R<sup>14</sup> is Leu or Nle,

R<sup>15</sup> is Gly, Ala, Abu, Nle or Gln,

R<sup>16</sup> is Gln or Arg,

R<sup>18</sup> is Ser or Nle,

R<sup>19</sup> is Ala ,

R<sup>21</sup> is Lys ,

R<sup>22</sup> is Leu, Ala or Aib,

RECEIVED

MAY 27 2003

TECH CENTER 1600/2900

R<sup>27</sup> is Met, Leu, Nle, Abu, or D-Arg,

R<sup>28</sup> is Arg, D-Arg, or Ser,

R<sup>29</sup> is Arg, D-Arg, Har or D-Har,

provided that where R<sup>9</sup> and R<sup>28</sup> are Ser, R<sup>29</sup> is other than Arg or Har,

and pharmaceutically acceptable salts thereof.

Claim 10. (previously amended) A method of treating a patient having a cancer carrying receptors for IGF-I or -II which comprises administering to said patient an effective amount of a peptide selected from the group having the formulae:

X-R<sup>1</sup>-R<sup>2</sup>-Asp-Ala-R<sup>5</sup>-R<sup>6</sup>-Thr-R<sup>8</sup>-R<sup>9</sup>-R<sup>10</sup>-Arg-R<sup>12</sup>-R<sup>13</sup>-R<sup>14</sup>-R<sup>15</sup>-R<sup>16</sup>-Leu-R<sup>18</sup>-R<sup>19</sup>-Arg-R<sup>21</sup>-R<sup>22</sup>-

Leu-Gln-Asp-Ile-R<sup>27</sup>-R<sup>28</sup>-R<sup>29</sup>-NH<sub>2</sub>

wherein X is PhAc, IndAc, or Nac,

R<sup>1</sup> is Tyr or His,

R<sup>2</sup> is D-Arg [or D-Cit],

R<sup>5</sup> is Ile or Val,

R<sup>6</sup> is Phe, Nal or Phe(Y), in which Y= Cl,

R<sup>8</sup> is Asn, Gln, Ala, or D-Asn,

R<sup>9</sup> is Arg, Har, Lys, Orn, D-Arg, D-Har, D-Lys, D-Orn, Cit, Nle, Tyr (Me), Ser, Ala or Aib,

R<sup>10</sup> is Tyr or or Tyr(Me),

R<sup>12</sup> is Lys,

R<sup>13</sup> is Val or Nle,

R<sup>14</sup> is Leu or Nle,

R<sup>15</sup> is Gly, Ala, Abu, Nle or Gln,

R<sup>16</sup> is Gln or Arg,

R<sup>18</sup> is Ser or Nle,

R<sup>19</sup> is Ala ,

R<sup>21</sup> is Lys ,

R<sup>22</sup> is Leu, Ala or Aib,

R<sup>27</sup> is Met, Leu, Nle, Abu, or D-Arg,

R<sup>28</sup> is Arg, D-Arg, or Ser,

R<sup>29</sup> is Arg, D-Arg, Har or D-Har,

provided that where R<sup>9</sup> and R<sup>28</sup> are Ser, R<sup>29</sup> is other than Arg or Har,

and pharmaceutically acceptable salts thereof .

Claim 11. (currently amended) A [a] method for inhibiting IGF-II levels in tumors (cancers) and the expression of mRNA for IGF-II in the same tumors in patients having such tumors, which comprises administering to said patient an effective amount a peptide selected from the group having the formulae:

X-R<sup>1</sup>-R<sup>2</sup>-Asp-Ala-R<sup>5</sup>-R<sup>6</sup>-Thr-R<sup>8</sup>-R<sup>9</sup>-R<sup>10</sup>-Arg-R<sup>12</sup>-R<sup>13</sup>-R<sup>14</sup>-R<sup>15</sup>-R<sup>16</sup>-Leu-R<sup>18</sup>-R<sup>19</sup>-Arg-R<sup>21</sup>-R<sup>22</sup>-

Leu-Gln-Asp-Ile-R<sup>27</sup>-R<sup>28</sup>-R<sup>29</sup>-NH<sub>2</sub>

wherein X is PhAc, IndAc, or Nac,

R<sup>1</sup> is Tyr or His,

R<sup>2</sup> is D-Arg [or D-Cit],

R<sup>5</sup> is Ile or Val,

R<sup>6</sup> is Phe, Nal or Phe(Y), in which Y= Cl,

R<sup>8</sup> is Asn, Gln, Ala, or D-Asn,

R<sup>9</sup> is Arg, Har, Lys, Orn, D-Arg, D-Har, D-Lys, D-Orn, Cit, Nle, Tyr (Me), Ser, Ala or Aib,

R<sup>10</sup> is Tyr or or Tyr(Me),

R<sup>12</sup> is Lys,

R<sup>13</sup> is Val or Nle,

R<sup>14</sup> is Leu or Nle,

R<sup>15</sup> is Gly, Ala, Abu, Nle or Gln,

R<sup>16</sup> is Gln or Arg,

R<sup>18</sup> is Ser or Nle,

R<sup>19</sup> is Ala ,

R<sup>21</sup> is Lys ,

R<sup>22</sup> is Leu, Ala or Aib,

R<sup>27</sup> is Met, Leu, Nle, Abu, or D-Arg,

R<sup>28</sup> is Arg, D-Arg, or Ser,

R<sup>29</sup> is Arg, D-Arg, Har or D-Har,

provided that where R<sup>9</sup> and R<sup>28</sup> are Ser, R<sup>29</sup> is other than Arg or Har,

and pharmaceutically acceptable salts thereof .

Claim 12. (previously added) The method of claim 9 which comprises administering a compound having the formula [PhAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 1.

Claim 13. (previously added) The method of claim 9 which comprises administering a compound having the formula [PhAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 3.

Claim 14. (previously added) The method of claim 10 which comprises administering a compound having the formula [PhAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 1.

Claim 15. (previously added) The method of claim 10 which comprises administering a compound having the formula [PhAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 3.

Claim 16. (previously added) The method of claim 11 which comprises administering a compound having the formula [PhAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 1.

Claim 17. (previously added) The method of claim 11 which comprises administering a compound having the formula [PhAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 3.